Vendor, Wien, AUT
Eveliqure Biotechnologies GMBH
UEI ZKEJW1JEKBQ9, CAGE 6311N
1 award and $4,881,502 obligated between June 3, 2024 and March 31, 2026, 100% under full and open competition, against 4.0 offers on average where reported.
Industries
NAICS on the awards, by dollars.
| Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)NAICS 541715 | $4,881,502 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition | 1 |
| Definitive Contract | 1 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75N93020C00048Definitive Contract, June 3, 2024, Full and Open Competition, 4 offers | National Institutes of Health NiaidNational Institutes of Health | To Advance the Development of the Shigetec Vaccine Through CGMP Manufacturing and Release of Additional CGMP Lots for Use in a Series of PhaNAICS 541715, PSC AN12 | $4,881,502 |
- Product and service codes
- AN12 Health R&D Services; Health Care Services; Applied Research
- Transactions
- 10 across 1 awards